Senaparib treatment outcomes in ovarian cancer patients
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tracks how well a drug called senaparib works for patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Researchers will observe patients receiving this treatment either alone or combined with other therapies to understand its real-world effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Confirmed diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (confirmed by tissue sample or cell analysis)
- Your doctor believes you are a good candidate for senaparib treatment
- If you can become pregnant, you must use effective birth control during the study and for 90 days after your last dose
- Not currently pregnant or breastfeeding
- Not enrolled in any other research studies with active treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Senaparib and Bevacizumab) as a first treatment after chemotherapy for women with advanced ovarian cancer that has a specific genetic feature called HRP. The goal is to see if this combination can help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial looks at how well PARP inhibitors (a type of targeted therapy) work for women with ovarian cancer. It includes women newly diagnosed with advanced cancer or those whose cancer came back after a long break from platinum chemo.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Hear when a new Ovarian Cancer (OvCa) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.